Effect of Intradialytic Intravenous Administration of ω-3 Fatty Acids on Nutritional Status and Inflammatory Response in Hemodialysis Patients: A Pilot Study

Short-term parenteral administration of ω-3 PUFA is safe and well-tolerated by HD patients. The intervention does not significantly influence markers of inflammation or change the nutritional status of chronic HD patients, but it may attenuate the inflammatory response to HD sessions.